ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports.

ALXO has been the topic of a number of other research reports. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Tuesday, August 13th. UBS Group reduced their price target on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Finally, Lifesci Capital cut shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, ALX Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $12.50.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.34 on Tuesday. The stock’s fifty day simple moving average is $1.73 and its 200 day simple moving average is $5.74. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52-week low of $1.30 and a 52-week high of $17.83.

Institutional Trading of ALX Oncology

Hedge funds have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology during the first quarter valued at about $27,000. EntryPoint Capital LLC bought a new position in ALX Oncology during the first quarter valued at about $32,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the period. SG Americas Securities LLC raised its holdings in ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $63,000. 97.97% of the stock is owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.